- Published at
- by gurufocus.com
mixed
mixed
Torex Gold Resources (TXG) Price Target Raised by Scotiabank | TXG Stock News
On June 4, 2025, Scotiabank's analyst Eric Winmill maintained his
News for 10x Genomics, Inc. (TXG.MX)
- Published at
- by gurufocus.com
positivepositiveARK Investment Acquires 290K Shares of 10x Genomics (TXG) | TXG Stock News
In a strategic move, Cathie Wood's ARK Investment Management has expanded its position in the genomics sector by purchasing 290,000 shares of 10x Genomics (TXG)- Published at
- by gurufocus.com
mixedmixedCathie Wood Big Sell-Off: Tesla and Palantir Holdings Dumped
June 3 - Cathie Wood's Ark Invest sold 1,594 shares of Tesla Inc (TSLA) through its ARK Innovation ETF (ARKK), offloading a position worth $546,247, according t- Published at
- by gurufocus.com
positivepositiveCathie Wood's ARK Investment Acquires Significant Stake in 10x Genomics (TXG) | TXG Stock News
ARK Investment, led by Cathie Wood, has made a substantial investment in 10x Genomics (TXG) by purchasing 335,000 shares. This move underscores ARK's confidence- Published at
- by benzinga.com
positivepositiveCathie Wood Sells Tesla Stock As Chinese Rivals Gain Ground — Ark Dumps Palantir Amid Privacy Concerns - ARK Innovation ETF (BATS:ARKK), Palantir Technologies (NASDAQ:PLTR)
On Monday, Cathie Wood-led Ark Invest sold shares of Tesla and Palantir, amidst competition and data misuse concerns. Ark also made significant trades in other companies, such as eToro and Illumina.- Published at
- by gurufocus.com
positivepositiveARK Investment Acquires 342K Shares of 10x Genomics (TXG) | TXG Stock News
ARK Investment Management, led by Cathie Wood, has expanded its holdings by purchasing 342,000 shares of 10x Genomics (TXG). This acquisition reflects ARK's ong- Published at
- by benzinga.com
positivepositiveCathie Wood Reiterates 'Profound' AI Application In Healthcare As Researchers Discover 'Cancer Survival Outcomes' By Facial Photograph Analysis: Here Are The Stocks That Could Benefit - Invesco QQQ Tr
Cathie Wood underscored the application of AI in the healthcare sector by sharing new research by Mass General Brigham.- Published at
- by gurufocus.com
neutralneutral10x Genomics (TXG) Price Target Lowered by Morgan Stanley | TXG Stock News
Morgan Stanley has updated its price target for 10x Genomics (TXG), adjusting it downwards from $26.00 USD to $18.00 USD. This change reflects a 30.77% decrease- Published at
- by gurufocus.com
neutralneutral10x Genomics (TXG) Sees Price Target Lowered by UBS | TXG Stock News
On May 13, 2025, UBS analyst Dan Leonard announced an update on 10x Genomics (TXG), maintaining a 'Neutral' rating but lowering the price target. The updated pr- Published at
- by gurufocus.com
neutralneutralGoldman Sachs Lowers Price Target for 10x Genomics (TXG) | TXG Stock News
In recent analyst activity, Goldman Sachs has adjusted its price target for 10x Genomics (TXG). The financial firm has maintained its "Sell" rating on the stock- Published at
- by gurufocus.com
positivepositive10x Genomics (TXG) Price Target Lowered by Canaccord Genuity | TXG Stock News
On May 12, 2025, Canaccord Genuity, under the guidance of analyst Kyle Mikson, announced an adjustment to their price target for 10x Genomics (TXG). The firm ma- Published at
- by gurufocus.com
neutralneutralCanaccord Adjusts 10x Genomics (TXG) Price Target Citing Market Uncertainty | TXG Stock News
Canaccord has revised its price target for 10x Genomics (TXG), dropping it from $18 to $15 while maintaining a Buy rating for the stock. This adjustment stems f- Published at
- by benzinga.com
mixedmixedCathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots - Amgen (NASDAQ:AMGN), Bristol-Myers Squibb (NYSE:BMY)
Cathie Wood highlights the rising applications of AI and how it is poised to impact the health care space.- Published at
- by gurufocus.com
neutralneutralStifel Adjusts 10x Genomics (TXG) Price Target Amid Funding Concerns | TXG Stock News
Stifel has revised its price target for 10x Genomics (TXG), reducing it from $18 to $15, yet maintaining a Buy rating on the stock. This adjustment follows the- Published at
- by gurufocus.com
positivepositive10x Genomics (TXG) Faces Price Target Reduction Amid Uncertain Outlook | TXG Stock News
TD Cowen analyst Dan Brennan has adjusted the price target for 10x Genomics (TXG), decreasing it to $11 from a previous target of $15 while maintaining a Hold r- Published at
- by gurufocus.com
positivepositiveJPMorgan Adjusts Price Target for 10x Genomics (TXG) Amid Market Concerns | TXG Stock News
JPMorgan has revised its price target for 10x Genomics (TXG), lowering it from $12 to $9, while maintaining a Neutral rating after the company's first-quarter r- Published at
- by gurufocus.com
positivepositive10x Genomics Inc (TXG) Q1 2025 Earnings Call Highlights: Navigating Challenges with Strategic Initiatives
Total Revenue: $154.9 million for Q1 2025.Adjusted Revenue: $138.1 million, down 2% year-over-year, excluding license and royalty revenue.Consumables Revenue:- Published at
- by benzinga.com
positivepositive10x Genomics CEO Calls NIH The 'Foundational Jewel' Of Biomedical Progress, Says 40% To 50% Of Revenue Supported By Academic And Government Research Funding — Pulls Full Year Revenue Guidance - 10x Ge
10x Genomics Inc. criticized U.S. government budget cuts for academic research, withdrew full-year guidance, and shifted to quarterly forecasts.- Published at
- by gurufocus.com
positivepositiveQ1 2025 10X Genomics Inc Earnings Call Transcript
May 08, 2025 / 08:30PM GMTOperator Ladies and gentlemen, thank you so much for standing by, and welcome to 10x Genomics first quarter 2025 earnings conference c- Published at
- by wallstreetpit.com
mixedmixedCathie Wood’s ARK Makes Bold Tuesday Moves with Key Stock Swaps
ARK ETFs sold 376,874 Palantir (PLTR) shares for $46.65 million, continuing a week-long reduction, while investing $10.45 million in 237,374 Guardant Health (GH) shares, signaling a shift from data analytics to precision oncology. Significant purchases included $10.17 million for 283,186 Twist Bioscience (TWST) shares and $8.75 million for 55,623 Natera…